Kiran joins TWiV to discuss the findings of a team at Columbia University Medical Center on COVID-19 neuropathology, and the conclusion that SARS-CoV-2 does not reproduce in the central nervous system.
In COVID-19 clinical update #73, Daniel Griffin reviews updated mask guidance from CDC, infections in public school district employees, effectiveness of vaccines against delta variant, antibody response after third vaccine dose in kidney transplant recipients, protection afforded by mRNA vaccines fully vaccinated people with and without prior infections, correlates of protection in nonhuman primates, lack of effectiveness of doxycycline, neurological manifestations of COVID-19, and infection in vaccinated health care workers.
TWiVsters review off-season epidemics of respiratory syncytial virus in Australia after easing of COVID-19 restrictions, and impaired innate immune responses in upper respiratory tract cells from patients with severe COVID-19.
In this special episode, Daniel Griffin answers listener questions on COVID-19 vaccines, vaccine misinformation, long COVID, masking and distancing, school safety, and much more.
In COVID-19 clinical update #72, Daniel Griffin covers long term symptoms in children, outcomes for MIS-C, recent guidance from the American Academy of Pediatrics, a large well traced outbreak of delta variant, low dose mRNA vaccination generates durable T cell memory and antibodies, protective immunity in recovered patients, assessment of BinaxNOW, no effect of oral azithromycin, post-discharge symptoms in Nigeria, and therapeutics for low and middle income countries.
In COVID-19 clinical update #71, Daniel Griffin reviews updated school and child care guidance from CDC, transmission in schools, accuracy of lateral flow assays, update to J&J/Janssen vaccine EUA to include GBS, interim immunogenicity of Ad.26.CoV2.s, effectiveness of mRNA vaccines to prevent hospitalization, Bamlanivimab plus Etesevimab for mild or moderate disease, and a meta-analysis of ivermectin results.
In COVID-19 clinical update #70, Daniel Griffin discusses efficacy of portable air cleaners, vaccine induced serum neutralizing antibodies against variants, prevention and attenuation of disease with mRNA vaccines, ivermectin to prevent hospitalization, IL-6 antagonists and mortality, and impact of vaccination on long COVID.
In COVID-19 clinical update #69, Daniel Griffin covers effectiveness of mRNA vaccines against the delta variant, depression among public health workers, correlates of protection against asymptomatic and symptomatic infection, BNT162b2 in ChAdOx-1-S primed individuals, prior infection rescues B and T cell responses to variants after vaccination, effect of vaccination on household transmission, germinal responses induced by mRNA vaccines, phase 3 results of Novavax vaccine, and long COVID as our next national health disaster.
In COVID-19 clinical update #68, Daniel Griffin discusses children acquiring infection at birthday parties, immunogenicity of vaccines in solid organ transplant patients, reinfection rates in recovered patients, lack of efficacy of azithromycin, bacterial and fungal infections in hospitalized patients, effect of monoclonal antibody treatment on clinical outcomes of ambulatory patients, and reduction in mortality of hospitalized patients treated with remedesivir.
In COVID-19 clinical update #67, Daniel Griffin reviews antibodies to the virus early in the US, serology testing of blood donations, MIS-C in children under 21, myocarditis in competitive athletes, ER visits for suspected suicide attempts, delta variant in Scotland, Novavax vaccine phase 3 results, vaccine coverage in pregnant women, early monoclonal administration reduces hospitalization and mortality, casirivimab and imdevimab recovery trial results, and CDC guidance on postacute sequelae.